C57BL/6 mouse splenocytes treated 48h with 2.5 μg/ml Concanavalin A were stained with either PerCP-Cy5.5 Rat IgG1, k Isotype Control (left panel) or SDT PerCP-Cy5.5 Rat Anti-Mouse CD134 Antibody at 1.25 μl/test treated with True-Stain Monocyte Blocker™. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
PerCP-Cy5.5 Rat Anti-Mouse CD134 Antibody (OX-86)
PerCP-Cy5.5 Rat Anti-Mouse CD134 Antibody (OX-86)
Price:
Regular price
$220 USD
Regular price
Sale price
$220 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD134 |
| Synonyms | Tumor necrosis factor receptor superfamily member 4; OX40 antigen; OX40L receptor; Ox40; Txgp1; Tnfrsf4 |
| Location | Membrane |
| Accession | P47741 |
| Clone Number | OX-86 |
| Antibody Type | Rat mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | Concanavalin A treated C57BL/6 mouse splenocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | PerCP-Cy5.5 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 0.25μg per million cells in 100μl volume | Ms |
Background
CD134, also known as TNFRSF4 or OX40, is a member of the tumor necrosis factor receptor superfamily. It is a co-stimulatory molecule primarily expressed on activated CD4+ and CD8+ T cells, as well as other immune cells such as natural killer (NK) cells and dendritic cells. Structurally, CD134 contains four TNFR-Cys repeats and interacts with its ligand, OX40L (TNFSF4), to activate downstream signaling pathways, including the NF-κB pathway through adaptor proteins like TRAF2 and TRAF5. This interaction promotes T cell proliferation, cytokine production, and enhances the survival of CD8+ T cells, playing a crucial role in immune responses. Additionally, CD134 has been implicated in various diseases, including cancer and autoimmune conditions, making it a target for immunotherapy and other therapeutic interventions.
Picture
Picture
FC
